Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.
On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.
Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.
Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.
Veracyte (Nasdaq: VCYT) announced that seven abstracts showcasing findings from the Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting from April 28 to May 1, 2023, in Chicago. The abstracts emphasize the clinical utility of the Decipher Prostate Genomic Classifier, aiding treatment decisions for prostate cancer patients. Notable presentations include studies on Molecular Correlates with PSMA Expression and the Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome. Veracyte aims to utilize this research to enhance patient care and treatment outcomes, reinforcing its commitment to evidence-based cancer treatment.
Veracyte (Nasdaq: VCYT) announced it will present three abstracts on its multi-omics capabilities at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled from April 14-19 in Orlando, Florida. The presentations will focus on advancements in oncology drug development, emphasizing tools like Brightplex and the Veracyte Biopharma Atlas. Notably, the abstracts cover topics such as single-cell resolution in tumor microenvironments and the integration of machine learning for colorectal cancer analysis. Veracyte aims to provide actionable insights for biopharma partners to enhance their development programs.
Veracyte, Inc. (NASDAQ: VCYT) has announced its financial standing as of December 31, 2022, following the Silicon Valley Bank events. The company reported $178.9 million in cash, cash equivalents, and short-term investments, primarily unaffected by the FDIC's actions regarding SVB. Veracyte maintains that its accessible financial resources will be adequate for ongoing operations and obligations. The company focuses on transforming cancer care, providing high-value diagnostic insights for various cancers and lung diseases, and aims to expand its testing capabilities globally.
Veracyte (NASDAQ: VCYT) has announced that CEO Marc Stapley and CFO Rebecca Chambers will present at two key investor conferences. The first is Cowen's 43rd Annual Health Care Conference in Boston on March 7, 2023, at 9:50 AM ET. The second event is the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 21, 2023, at 3:45 PM ET. Live webcasts of these presentations can be accessed via Veracyte’s website, with replays available for 90 days post-event. Veracyte aims to transform cancer care globally with innovative diagnostic tests that help clinicians make better decisions and improve patient outcomes.
Veracyte reported fourth quarter 2022 revenue of $80.3 million, up 19% from $67.3 million in Q4 2021, and total revenue for 2022 reached $296.5 million, a 35% increase year-over-year. Testing revenue for the quarter was $70.3 million, reflecting a 32% growth, driven by Decipher and Afirma tests. Despite a 39% decline in biopharmaceutical revenue, overall gross margin improved to 61%. The net loss for the quarter was $3.8 million, improved 63% year-over-year. For 2023, Veracyte projects total revenue between $325 million and $335 million, indicating mid-teens growth in testing and product revenues.
Veracyte, Inc (Nasdaq: VCYT) announced that the Decipher Prostate Genomic Classifier significantly improves risk stratification for men with clinically high-risk prostate cancer. Data published in the International Journal of Radiation Oncology, Biology, Physics from three phase 3 trials validate that the Decipher test provides clinically useful prognostic information. High-risk prostate cancer affects about 30% of newly diagnosed patients, yet many of them may not require aggressive treatments. The Decipher test categorizes patients based on cancer aggressiveness and can influence treatment decisions, potentially impacting overall survival, prostate cancer-specific mortality, and distant metastases.
Veracyte (NASDAQ: VCYT) revealed new insights from the G-MINOR trial at the 2023 ASCO GU Symposium, highlighting the Decipher Prostate Genomic Classifier's clinical utility. The study analyzed data from 1,015 men with prostate cancer, determining that tumor classification by subtype can inform treatment responses. Findings indicated luminal differentiated tumors had the best prognosis post-surgery, while basal immune tumors benefitted most from radiotherapy. Additionally, patients who underwent Decipher testing did not experience significant quality-of-life changes despite increased adjuvant therapy. This reinforces Veracyte's commitment to precision medicine in prostate cancer treatment.
Veracyte (Nasdaq: VCYT) is set to announce its financial results for Q4 2022 and the full year after market close on February 22, 2023. A conference call featuring management will be held at 4:30 p.m. ET the same day, providing insights into the company's financial performance and strategic updates. The call will be available via webcast on the company's website, ensuring broad access for stakeholders. Veracyte is dedicated to enhancing cancer care globally through high-value diagnostic insights, particularly for complex cancers like thyroid and prostate.
Veracyte (NASDAQ: VCYT) announced the presentation of six abstracts at the 2023 ASCO Genitourinary Cancers Symposium from February 16-18, 2023. These presentations highlight advancements in the Decipher urologic cancer testing offerings and utilize insights from Veracyte's Decipher Genomics Resource for Intelligent Discovery (GRID) database. Notably, the data aims to enhance treatment personalization for prostate cancer patients. The company emphasizes its commitment to empowering physicians with actionable genomic insights to better inform treatment decisions for urologic cancers.
Veracyte (VCYT) announces findings published in Frontiers in Endocrinology, revealing insights into the frequency and risk of malignancy linked to thyroid stimulating hormone receptor (TSHR) mutations in indeterminate thyroid nodules. Analysis of 8,881 nodules showed that only 5% were classified as suspicious for cancer. The risk of malignancy for benign nodules is ≤4%, while those identified as suspicious by the Afirma Genomic Sequencing Classifier (GSC) have a 15.3% risk. These results underscore the potential of Afirma testing for personalized care in thyroid nodule diagnosis and treatment.